• Vaccine Name: ERA005f
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: ERA005f is a fusion protein composed of ESAT-6 (Rv3875), Rv2628, and Ag85B (Rv1886c) M. tuberculosis antigens (Fan et al., 2023).
• Ag85B from M. tuberculosis H37Rv gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Fan et al., 2023).
  • Detailed Gene Information: Click Here.
• EsxA (ESAT-6) gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Fan et al., 2023).
  • Detailed Gene Information: Click Here.
• Rv2628 gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Fan et al., 2023).
  • Detailed Gene Information: Click Here.
• Adjuvant: aluminum hydroxide vaccine adjuvant
  • Adjuvant name: aluminum hydroxide vaccine adjuvant
  • VO adjuvant ID: VO_0000127
  • Description: alum is used as an adjuvant to enhance antigen presentation and stimulate a stronger immune response (Fan et al., 2023).
• Preparation: The ERA005f fusion protein was expressed in E. coli, purified using nickel affinity and ion-exchange chromatography, refolded, and then mixed with alum adjuvant (Fan et al., 2023).
• Immunization Route: subcutaneous injection
• Description: ERA005f is a multistage recombinant fusion protein tuberculosis vaccine formulated with alum that induces strong Th1 and Th17 immune responses and inhibits Mycobacterium tuberculosis growth in a mouse model (Fan et al., 2023).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were immunized three times at 0, 2, and 4 weeks, and samples were collected 10 days after the final immunization (Fan et al., 2023).
• Challenge Protocol: Protection was evaluated using a Mycobacterial Growth Inhibition Assay (MGIA) rather than in vivo aerosol challenge (Fan et al., 2023).
• Efficacy: ERA005f significantly reduced H37Rv bacterial growth in mouse splenocytes (approximately 0.88 log10 CFU reduction compared to PBS control) (Fan et al., 2023).
• Information about this animal model: Mouse Model for TB research